Business Context and Reporting Period
This Form 8-K is a current report filed by Emerald Bioscience, Inc. (not Skye Bioscience, Inc.) on September 25, 2020. The filing addresses corporate governance changes under Item 5.02 regarding the departure of an interim officer and the appointment of a new interim Principal Accounting Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed relates to the compensation arrangement for the new interim officer:
- Compensation Rate: $300 per hour for the interim Principal Accounting Officer's work.
- Advisory Rate: $275 per hour for other financial advisory services provided by the firm RoseRyan, Inc.
- Contract Term: Up to 90 days.
Material Changes
The primary material change reported is the leadership transition in the finance department:
- Departure: Ms. Elena Traistaru stepped down as interim Principal Financial Officer effective September 25, 2020, due to personal reasons. The filing states there was no disagreement with the Company.
- Appointment: Mr. Richard Janney was appointed as interim Principal Accounting Officer, effective September 28, 2020. He will serve as an independent contractor through RoseRyan, Inc.
Outlook, Risks, and Management Commentary
Management Commentary: The Company emphasized that the departure of the previous officer was not related to any disagreement regarding operations, policies, or practices. The new appointee, Mr. Janney, brings experience as a former CFO of public companies (Thinc, Inc., Trident Microsystems, Inc., Asyst Technologies, Inc.) and a manager at PricewaterhouseCoopers.
Risks and Contingencies: The filing notes that Mr. Janney and RoseRyan are subject to customary confidentiality provisions, and the Company is subject to customary non-solicitation provisions. No other specific risks or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the correct registrant name is Emerald Bioscience, Inc. (the input metadata incorrectly listed Skye Bioscience, Inc.).
- Confirm the effective date of Mr. Janney's appointment (September 28, 2020) versus the departure date (September 25, 2020).
- Review the 90-day contract term to determine if a permanent CFO search is underway.
- Check subsequent filings for any financial statements reviewed by the new interim officer.